Cargando…

Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer

For the past several decades, cancer patients in the U.S. have chosen the use of natural products as an alternative or complimentary medicine approach to treat or improve their quality of life via reduction or prevention of the side effects during or after cancer treatment. The genus Ganoderma inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Suárez-Arroyo, Ivette J., Loperena-Alvarez, Yaliz, Rosario-Acevedo, Raysa, Martínez-Montemayor, Michelle M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533290/
https://www.ncbi.nlm.nih.gov/pubmed/28758107
http://dx.doi.org/10.3390/medicines4010015
_version_ 1783253596871065600
author Suárez-Arroyo, Ivette J.
Loperena-Alvarez, Yaliz
Rosario-Acevedo, Raysa
Martínez-Montemayor, Michelle M.
author_facet Suárez-Arroyo, Ivette J.
Loperena-Alvarez, Yaliz
Rosario-Acevedo, Raysa
Martínez-Montemayor, Michelle M.
author_sort Suárez-Arroyo, Ivette J.
collection PubMed
description For the past several decades, cancer patients in the U.S. have chosen the use of natural products as an alternative or complimentary medicine approach to treat or improve their quality of life via reduction or prevention of the side effects during or after cancer treatment. The genus Ganoderma includes about 80 species of mushrooms, of which several have been used for centuries in traditional Asian medicine for their medicinal properties, including anticancer and immunoregulatory effects. Numerous bioactive compounds seem to be responsible for their healing effects. Among the approximately 400 compounds produced by Ganoderma spp., triterpenes, peptidoglycans and polysaccharides are the major physiologically-active constituents. Ganoderma anticancer effects are attributed to its efficacy in reducing cancer cell survival and growth, as well as by its chemosensitizing role. In vitro and in vivo studies have been conducted in various cancer cells and animal models; however, in this review, we focus on Ganoderma’s efficacy on breast cancers. Evidence shows that some species of Ganoderma have great potential as a natural therapeutic for breast cancer. Nevertheless, further studies are needed to investigate their potential in the clinical setting and to translate our basic scientific findings into therapeutic interventions for cancer patients.
format Online
Article
Text
id pubmed-5533290
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-55332902017-07-28 Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer Suárez-Arroyo, Ivette J. Loperena-Alvarez, Yaliz Rosario-Acevedo, Raysa Martínez-Montemayor, Michelle M. Medicines (Basel) Review For the past several decades, cancer patients in the U.S. have chosen the use of natural products as an alternative or complimentary medicine approach to treat or improve their quality of life via reduction or prevention of the side effects during or after cancer treatment. The genus Ganoderma includes about 80 species of mushrooms, of which several have been used for centuries in traditional Asian medicine for their medicinal properties, including anticancer and immunoregulatory effects. Numerous bioactive compounds seem to be responsible for their healing effects. Among the approximately 400 compounds produced by Ganoderma spp., triterpenes, peptidoglycans and polysaccharides are the major physiologically-active constituents. Ganoderma anticancer effects are attributed to its efficacy in reducing cancer cell survival and growth, as well as by its chemosensitizing role. In vitro and in vivo studies have been conducted in various cancer cells and animal models; however, in this review, we focus on Ganoderma’s efficacy on breast cancers. Evidence shows that some species of Ganoderma have great potential as a natural therapeutic for breast cancer. Nevertheless, further studies are needed to investigate their potential in the clinical setting and to translate our basic scientific findings into therapeutic interventions for cancer patients. MDPI 2017-03-15 /pmc/articles/PMC5533290/ /pubmed/28758107 http://dx.doi.org/10.3390/medicines4010015 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Suárez-Arroyo, Ivette J.
Loperena-Alvarez, Yaliz
Rosario-Acevedo, Raysa
Martínez-Montemayor, Michelle M.
Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer
title Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer
title_full Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer
title_fullStr Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer
title_full_unstemmed Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer
title_short Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer
title_sort ganoderma spp.: a promising adjuvant treatment for breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533290/
https://www.ncbi.nlm.nih.gov/pubmed/28758107
http://dx.doi.org/10.3390/medicines4010015
work_keys_str_mv AT suarezarroyoivettej ganodermasppapromisingadjuvanttreatmentforbreastcancer
AT loperenaalvarezyaliz ganodermasppapromisingadjuvanttreatmentforbreastcancer
AT rosarioacevedoraysa ganodermasppapromisingadjuvanttreatmentforbreastcancer
AT martinezmontemayormichellem ganodermasppapromisingadjuvanttreatmentforbreastcancer